Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Hunan Province Tumor Hospital60 enrolled

Overview

The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

First line EC/EP+AtezolizumabDRUG

Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy Exclusion Criteria: \- Patients with contraindication of chemotherapy Pregnant or breast feeding women

Locations (1)

Hunan Cancer Hospital

Changsha, Hunan, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: April 2019- July 2021

Overall survival

Time frame: April 2019- July 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.